Skip to main content

Bacteriophage Therapy to Treat Acne Caused By Specific Strains of Bacteria

 The microbiome of humans consists of different microorganisms that both live inside and outside the body, in which the skin, the oral mucosa, and the gastrointestinal tracts are the most common habitat for the complex microbial community. Each individual has different microbiome composition and forms a symbiotic association with them. Take the skin microbiome as an example, it's made up of diverse organisms such as different strains of bacteria, viruses, and fungi, and usually, they live in a state of balance. But when alterations occur, the skin microbiome may lead to some skin diseases, such as acne vulgaris. Acne vulgaris is one of the most common inflammatory skin conditions, which is related to a gram-positive bacterium, Cutibacterium acnes (C. acnes).

 

C. acnes is the most abundant skin commensal of the human skin microbiome and has different strains, some of which predominate in healthy skin and others are associated with acne. Healthy skin means different microorganisms live in a balance, while acne indicates a change in the abundance of certain strains and an imbalance.

 

However, using antibiotics to treat acne is not the best choice, in that antibiotic treatments would not only kill specific strains of C. acnes causing acne but also other bacteria in the skin microbiome, thus leading to another dysbiosis. Therefore, the  Translational Synthetic Biology research group at Universitat Pompeu Fabra presents a new approach to killing specific strains of a bacterium related to acne without affecting the balance of the skin microbiome.

 

Bacteriophage therapy to manipulate the skin microbiome

 

The new strategy to eliminate acne-specific strains of bacteria is based on the finding of the viruses in the skin microbiome—bacteriophages, or simply called phages. Phages within the skin microbiome can regulate the microbial composition by infecting either narrow strains of bacteria or broadly within a population, which is known as phage therapy. Researchers have found that C. acnes has multiple temperate and lytic phages that can switch between different infection modes and significantly affect the microbial community. The lytic cycle of phages can kill and solubilize host bacteria, whereas the lysogenic cycle can impact host cells more subtly, both physiologically and genetically.

 

Researchers pointed out that, though C. acnes phages have more than 85% overall sequence identity, they have diverse ability to infect certain strains of bacteria. PAD20 is one of the well-studied C. acnes bacteriophages, which wasn't strictly identified as a lytic or lysogenic phage due to the absence of stable lysogens and the absence of genes related to integration. Therefore, researchers studied the potential of PAD20 in killing various C. acnes strains and linked the increase of its specificity to phage DNA methylation acquired through infection of a methylation competent strain.

 

Studies have shown that some strains of C. acnes in the skin microbiome can introduce modifications to their own genome and differentiate their own from non-own to prevent infection by bacteriophages. A conclusion has been drawn that bacteria without the ability to modify their own DNA were infected strongly by the bacteriophage while the modified bacteria were immune to the infection. To eliminate these specific strains related to acne identified, scientists proposed a mechanism of selectively killing a certain sub-population of strains by making the therapeutic phages target only strains that can't modify their own DNA.

 

It turns out that bacteriophage therapy can modulate the composition of C. acnes strains over time. As a result, the acne-prone strains are reduced while strains with beneficial traits can be saved.

 

In conclusion, this study reveals the potential to shape and engineer the infectivity range of C. acnes phages for the development of phage therapy. Moreover, it proves that epigenetic imprinting of phage DNA can change the susceptibility of phages on their host and can change specificity in infection, which opens the door for developing phage cocktails that could potentially modulate strain composition on human skin in further applications.

Comments

Popular posts from this blog

Everything You Want to Know About Antibody Development

  Everything You Want to Know About Antibody Development   When foreign molecules, which are known as antigens, enter our body, antibodies will be released by B cells of the immune system to specifically bind to the antigens and finally clear out those “invaders”. Such a highly specific molecular recognition mechanism has inspired a variety of antibody development research and diagnostic applications nowadays, including IVD antibody development .   What is Antibody Development?   Antibody development is the process of creating and characterizing an antibody.   The timeline of developing antibodies starts from the injection of an antigen of interest into a host animal, so that the host’s immune system can detect it and generat e  the desired antibodies. Then, antibody development proceeds with finding and isolating the desired antibodies from the rest of the protein in sera.   The reset procedure of antibody development is varied as the desired antibodi...

An Overview of the Global Bispecific Antibody Therapeutics Market

  Antibod ies , a major component of adaptive immunity, play a critical role in protective and pathogenic immune responses. In r ecent years, a wide range of antibodies is discovered as candidates of cancer therapeutic agents, including the reconstructive molecules, bispecific antibodies (BsAbs).   About Bispecific Antibody   Bispecific antibodies, as its name indicates, consists of two antigen-binding sites, which can simultaneously bind two separate and unique antigens (or different epitopes of the same antigen). This structure is  typically designed to bind to two targets, one on a cancer cell and one on an immune cell, act ivating or redirecting immune effector cells with the goal of getting the immune cell to kill the cancer cell by antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC) and other cytotoxic mechanisms.   U nique biological and pharmacological properties, ...

Unmodified Bacteriophages Research Updates

  R ecent research conducted by researchers from Yale University is published in  Applied and Environmental Microbiology , suggesting  that natural bacteriophage, or phage, can kill dysentery-causing bacteria and reduce virulence in surviving bacteria. It's a piece   of  inspiring news as  treating dysentery has become a challenge with the rising antibiotic resistance.   Background   Shigella flexneri , the culprit causing contagious infection marked by inflammatory diarrhea and dysentery in sub-Saharan Africa and southern Asia, kills about 160,000 people globally every year. The World Health Organization (WHO) takes priority to this pathogen in terms of increasing cases, antimicrobial resistance, and limited treatment options.   S. flexneri  is active primarily in low-income countries, like southern Asia and sub-Saharan Africa. In these places, dirty drinking water is a concern causing dysentery, while antibiotics are expensive and unav...